Enhanced Anticancer Efficacy of Noscapine-Loaded Lipid Nanocapsules: In-vitro and In-vivo Evaluation.

Abdel-Wahab, Nadeen Diaa; Kabil, Mohamed Fawzi; El-sherbiny, Ibrahim M.; Salama, Mohamed F.; El-Sayed, Gehad; El-Sherbini, El-Said

doi:10.21608/ejchem.2024.259976.9129

Enhanced Anticancer Efficacy of Noscapine-Loaded Lipid Nanocapsules: In-vitro and In-vivo Evaluation.

Document Type : Original Article

Authors

¹ Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Mansoura University, Egypt

² Nanomedicine Research Labs, Center for Materials Science, Zewail City of Science and Technology, 6th of October City, Giza, Egypt

10.21608/ejchem.2024.259976.9129

Abstract

Noscapine (NOS), an alkaloid with several interesting biological applications, has demonstrated antitumor action and cough suppressant potential. However, the strong hydrophobic nature of NOS makes it poorly water-soluble. Therefore, it was necessary to figure out how to make NOS more soluble. In this study, we investigated the anticancer effect of free NOS as compared to that of NOS-loaded lipid nanocapsules (NOS-LNCs) on the 4T1 cell line, and in an orthotopic breast cancer (BC) mouse model. Spherical-shaped NOS-LNCs were prepared with a particle size (PS) of 213.4 ± 1.41 nm and a zeta potential (ZP) of -13.6 ± 1.17. The IC50 of free NOS, NOS-LNCs, and plain LNCs was measured on the 4T1 cell line by MTT assay, and the results revealed that the IC50 was 66.107 µg/ml, 13.209 µg/ml, and 121.132 µg/ml, respectively. On the other hand, NOS-LNCs demonstrated stronger anticancer effects in-vivo along with strong antiproliferative and antioxidant properties. Also, the immunohistochemistry analysis of BAX and BCL-2 in the tumor tissue confirmed the apoptotic activity of the NOS-LNCs, as it increased the expression of BAX and downregulated BCL-2. In conclusion, the current investigation showed that the developed NOS nanoform has a great deal of potential as a therapeutic agent for the treatment of BC.

Keywords

Main Subjects